Advent Life Sciences
London-based trans-Atlantic venture and growth investor backing life sciences and drug discovery companies across the UK, Europe and the United States.
Advent Life Sciences is a London-based venture and growth investor focused on life sciences businesses in the UK, Europe and the United States. The firm backs companies that translate scientific research into medicines and other products, with an emphasis on drug discovery, translational science and pharmaceutical development. Its investment activity, referenced since 2006, spans two complementary approaches: early-stage venture investing in companies working to move research towards the clinic, and growth-equity capital for more mature life sciences businesses across the same three markets.
The firm operates as a dedicated life sciences team within Advent Venture Partners. Its stated track record includes 15 approved medicines and products discovered and developed by portfolio companies - a measure that reflects a strategy oriented towards outcomes rather than transaction volume. The firm describes the path from scientific research to approved medicine as long, difficult and complex, and positions itself accordingly with a long-term orientation and an experienced team with entrepreneurial and investment backgrounds.
Geographically, Advent Life Sciences is trans-Atlantic by design, investing from a London base across the United Kingdom, Europe and the United States. The sectors of focus - life sciences, biotechnology, pharmaceuticals and drug discovery - define a specialist mandate within the broader venture and growth-equity landscape.